Schamaun M
Abteilung für Thorax- und Gefässchirurgie, Stadtspital Triemli, Zürich.
Schweiz Med Wochenschr. 1987 Sep 26;117(39):1498-505.
117 patients with stage III bronchogenic carcinoma (AJC) underwent thoracotomy after careful staging between 1977 and 1985. 13 patients were found to be inoperable, while in 104 resection was performed. Operative mortality was 8.5% for 82 patients with curative resection and 27% for 22 patients with non-curative resection. Histologically there were 64 epidermoid and 23 adenomatous carcinomas. 79 of the 117 patients had lymph node metastases, 49 of them in mediastinal (N2) nodes of whom 42 could be resected. The absolute 5-year survival rate amounted to 9% for all 104 patients, 12% for 82 patients following curative resection and 0% for 22 patients following non-curative resection. 14% of the latter patients survived for two years. Survival rate after to years was 29% for patients in stage T3N0 + T3N1 and 35% for those in stage T1, T2, T3N2, but 15% and 0% respectively after five years. 5-year survival rate was 15% for patients with epidermoid carcinoma, but 0% for adenomatous carcinoma. Mean survival time for the 58 patients who died late following curative resection was 14.3 months, for those with epidermoid carcinoma 15.9 months and with adenomatous carcinoma 15.4 months, following pneumonectomy 13.1 months and following partial resection 17 months, and for the 16 patients who died late after non-curative resection 12.7 months. It was not influenced by postoperative irradiation in 20 patients (13 months). No statistical significance could be demonstrated for all these results. Nevertheless, they seem to indicate that in stage III bronchogenic carcinoma patients with epidermoid type have a fairly good prognosis, while with mediastinal lymph node metastasis the outcome is poor.(ABSTRACT TRUNCATED AT 250 WORDS)
1977年至1985年间,117例III期支气管源性癌(AJC)患者在经过仔细分期后接受了开胸手术。发现13例患者无法手术,而104例患者进行了切除手术。82例根治性切除患者的手术死亡率为8.5%,22例非根治性切除患者的手术死亡率为27%。组织学检查发现有64例鳞状细胞癌和23例腺癌。117例患者中有79例有淋巴结转移,其中49例转移至纵隔(N2)淋巴结,42例可切除。104例患者的绝对5年生存率为9%,82例根治性切除患者为12%,22例非根治性切除患者为0%。后者中有14%的患者存活了两年。T3N0 + T3N1期患者10年生存率为29%,T1、T2、T3N2期患者为35%,但5年后分别为15%和0%。鳞状细胞癌患者的5年生存率为15%,腺癌患者为0%。58例根治性切除后晚期死亡患者的平均生存时间为14.3个月,鳞状细胞癌患者为15.9个月,腺癌患者为15.4个月,肺叶切除术后为13.1个月,部分切除术后为17个月,16例非根治性切除后晚期死亡患者为12.7个月。20例患者(13个月)接受术后放疗后生存时间未受影响。所有这些结果均无统计学意义。然而,它们似乎表明,III期支气管源性癌患者中,鳞状细胞类型预后较好,而有纵隔淋巴结转移者预后较差。(摘要截短至250字)